



## Antidiabetic Noninsulin Agent Prior Authorization of Benefits Form

health link llo

## CONTAINS CONFIDENTIAL PATIENT INFORMATION

Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 1-844-512-9004. Provider Help Desk: 1-800-454-3730

1. Patient information		2. Physician informat	2. Physician information			
Patient name:		Prescribing physician:	Prescribing physician:			
Patient ID #:		Physician address:	Physician address:			
Patient DOB:		Physician phone #:	Physician phone #:			
Date of Rx:		Physician fax #:	Physician fax #:			
Patient phone #:		Physician specialty:	Physician specialty:			
Patient email address:		Physician DEA:	Physician DEA:			
		Physician NPI #:				
		Physician email addres	Physician email address:			
3. Medication	4. Strength	5. Directions	6. Quantity per 30 days			
			Specify:			
7. Diagnosis:						

**8.** Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.)

Prior authorization is required for preferred antidiabetic, noninsulin agents subject to clinical criteria. Payment will be considered under the following conditions:

- 1. Patient has an FDA approved or compendia indicated diagnosis
- 2. Patient meets the FDA approved or compendia indicated age
- 3. For the treatment of Type 2 Diabetes Mellitus, the patient has not achieved HgbA1Cgoals after a minimum three month trial with metformin at a maximally tolerated dose.
- 4. Requests for non-preferred anti-diabetic, non-insulin agents subject to clinical criteria will be authorized only for cases in which there is documentation of previous trials and therapy failures with a preferred drug in the same class. Requests for a non-preferred agent for the treatment of Type 2 Diabetes Mellitus must document previous trials and therapy failures with metformin, a preferred DPP-4 Inhibitor or DPP-4 Inhibitor combination, a preferred Incretin Mimetic, and a preferred SGLT2 Inhibitor at maximally tolerated doses.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Initial authorizations will be approved for six months. Additional prior authorizations will be considered on an individual basis after review of medical necessity and documented continued improvement in symptoms (such as HgbA1C for Type 2 Diabetes).

Preferred DPP-4 inh	ibitors and combos	Nonn	oreferred DPP-4 inhibit	ors and combinations				
□ Janumet			ogliptin	Glyxambi	🗆 Kombiglyze XR 🛛 Oseni			
□ Janumet XR			ogliptin-Metaformin		□ Nesina			
🗆 Januvia			ogliptin-Pioglitazone		□ Onglyza			
Preferred incretin mimetics Nonpreferred incretin mimetics								
	□ Ozempic		□ Adlyxin	Rybelsus				
□ Bydureon	•		Bydureon BCise	•				
			,	,				
Preferred SGLT2 inhibitors and combinations Nonpreferred SGLT2 inhibitors and combinations								
□ Jardiance	🗆 Synjardy		🗆 Invokamet	□ Otern	🗆 Steglujan			
🗆 Farxiga	,,,,		🗆 Invokamet XR	□ Segluromet	🗆 Xigduo XR			
-			🗆 Invokana	□ Steglatro	🗌 Synjardy XR			
				5				
Metformin trial								
Trial start date:		Trial end date:		Trial of	Trial dose:			
Reason for failure:								
Medical or contraine	dication reason to o	overric	le trial requirements:					
			Date thi	is level was obtained:				
Requests for nonpre	•							
Preferred DPP-4 tria	ll: drug name/dos	e:						
Trial start date:		Tria	lend date:					
Reason for failure:								
Trial start date: Tri			lend date:					
Reason for failure:								
Preferred SGLT2 tria	al: drug name/dos	e:						
			l end date:					
Reason for failure: _								
Reason for use of nonpreferred drug requiring prior approval:								
Attach lab results and other documentation as necessary.								
9. Physician signatu	ire							
				<u> </u>				
Prescriber or author	ized signature			Date				
	<b>(</b> )							
		•	-	•	dependent medical judgment			
of a treating physician. Only a treating physician can determine what medications are appropriate for a patient.								
Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and								
exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the								
requested services are medically indicated and necessary to the health of the patient.								
Note: Payment is subject to member eligibility. Authorization does not guarantee payment.								